Novel antifungal shows promise for patients with refractory disseminated coccidioidomycosis

1. In this single-group, open-label trial, olorofim was associated with a complete or partial clinical response in over 75% of patients with disseminated coccidioidomycosis (DCM) and limited or no treatment options. 2. Clinical success rates were highest among patients without central nervous system (CNS) infection. Evidence Rating Level: 2 (Good) Study Rundown: Every year, thousands […] The post…